Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

Peter L Greenberg1, Neal S Young, Norbert Gattermann

  • 1Hematology Division, Stanford University Medical Center, CA 94305, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia.

NEJM evidence·2026
Same author

Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.

Leukemia·2026
Same author

Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia.

HemaSphere·2026
Same author

T cell and monocyte activation in concert with hematopoietic stem cell interactions shapes the post-allogeneic transplant immune landscape in poor graft function.

Frontiers in immunology·2026
Same author

Reframing-renaming(?)-myelodysplastic syndromes/neoplasms and clonal hematopoiesis of indeterminate potential.

Leukemia·2026
Same author

STAT3 SH2 Domain Aspartic Acid 661 Mutations Activate Immune Gene Programs.

Journal of cellular and molecular medicine·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Myelodysplastic syndromes (MDS) involve stem cell issues, immune problems, and mitochondrial dysfunction, leading to blood deficiencies and leukemia risk. New therapies target these abnormalities for better patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Myelodysplastic syndromes (MDS) cause blood deficiencies and increase leukemia risk.
  • MDS pathogenesis involves stem cell defects, immune dysregulation, and stromal abnormalities.
  • Patient age and disease heterogeneity complicate MDS treatment.

Purpose of the Study:

  • Review current understanding of MDS biologic and molecular lesions.
  • Discuss emerging biospecific drugs for MDS treatment.
  • Explore decision-making for therapeutic options based on patient factors and risk.

Main Methods:

  • Review of current literature on MDS pathogenesis and treatment.
  • Discussion of immunologic mechanisms in MDS, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Related Experiment Videos

  • Analysis of ring sideroblasts and mitochondrial dysfunction in MDS.

    • Main Results:

    • MDS involves stem cell lesions, immune derangements, and stromal defects.
    • Immunologic attack on hematopoietic stem cells contributes to marrow failure in some MDS patients.
    • Mitochondrial dysfunction, indicated by ring sideroblasts, is linked to aging and toxic iron accumulation.

    Conclusions:

    • Understanding MDS molecular and biologic lesions is crucial for developing targeted therapies.
    • Immune modulation and biospecific drugs offer new therapeutic strategies for MDS.
    • Mitochondrial iron accumulation due to respiratory chain malfunction is a key pathophysiological process in MDS.